FOI_6552

Internal Reference Number: FOI_6552

Date Request Received: 13/04/2022 00:00:00

Date Request Replied To: 12/05/2022 00:00:00

This response was sent via: By Email

Request Summary: Treatment of dermatological conditions

Request Category: Companies


Question Number 1: How many patients were treated in last 4 months by the Dermatology department with each of the following: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Tacrolimus ointment • Tralokinumab • Upadacitinib

Answer To Question 1: Abrocitinib 0 Acitretin 25 Alitretinoin 8 Azathioprine 5 Baricitinib 0 Ciclosporin 9 Dupilumab 15 Methotrexate 16 Mycophenolate <5 Pimecrolimus 15 Tacrolimus ointment 25 Tralokinumab 0 Upadacitinib 0

Question Number 2: Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?

Answer To Question 2: None

Question Number 3: How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic Dermatitis ONLY?

Answer To Question 3: From the 01/01/22- 30/4/2022 we have had 10 patients attend the department for PUVA/UVB treatment for atopic dermatitis only.

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.